Daxor (DXR) Competitors $9.01 +0.19 (+2.15%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends DXR vs. ARAY, NVRO, DRTS, BWAY, PDEX, KRMD, SRTS, TLSI, INO, and QIPTShould you be buying Daxor stock or one of its competitors? The main competitors of Daxor include Accuray (ARAY), Nevro (NVRO), Alpha Tau Medical (DRTS), BrainsWay (BWAY), Pro-Dex (PDEX), KORU Medical Systems (KRMD), Sensus Healthcare (SRTS), TriSalus Life Sciences (TLSI), Inovio Pharmaceuticals (INO), and Quipt Home Medical (QIPT). These companies are all part of the "surgical & medical instruments" industry. Daxor vs. Accuray Nevro Alpha Tau Medical BrainsWay Pro-Dex KORU Medical Systems Sensus Healthcare TriSalus Life Sciences Inovio Pharmaceuticals Quipt Home Medical Accuray (NASDAQ:ARAY) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, community ranking, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends. Does the MarketBeat Community prefer ARAY or DXR? Accuray received 331 more outperform votes than Daxor when rated by MarketBeat users. However, 100.00% of users gave Daxor an outperform vote while only 65.61% of users gave Accuray an outperform vote. CompanyUnderperformOutperformAccurayOutperform Votes33265.61% Underperform Votes17434.39% DaxorOutperform Votes1100.00% Underperform VotesNo Votes Which has higher valuation and earnings, ARAY or DXR? Daxor has lower revenue, but higher earnings than Accuray. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAccuray$446.55M0.38-$15.55M-$0.17-10.00DaxorN/AN/AN/AN/AN/A Is ARAY or DXR more profitable? Daxor has a net margin of 0.00% compared to Accuray's net margin of -3.72%. Daxor's return on equity of 0.00% beat Accuray's return on equity.Company Net Margins Return on Equity Return on Assets Accuray-3.72% -36.93% -3.52% Daxor N/A N/A N/A Do institutionals & insiders have more ownership in ARAY or DXR? 64.1% of Accuray shares are held by institutional investors. Comparatively, 1.3% of Daxor shares are held by institutional investors. 4.2% of Accuray shares are held by company insiders. Comparatively, 59.0% of Daxor shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, ARAY or DXR? Accuray has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Daxor has a beta of -0.54, meaning that its share price is 154% less volatile than the S&P 500. Do analysts prefer ARAY or DXR? Accuray currently has a consensus price target of $9.00, indicating a potential upside of 429.41%. Daxor has a consensus price target of $24.75, indicating a potential upside of 174.69%. Given Accuray's higher probable upside, equities analysts plainly believe Accuray is more favorable than Daxor.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Accuray 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Daxor 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to ARAY or DXR? In the previous week, Accuray had 2 more articles in the media than Daxor. MarketBeat recorded 3 mentions for Accuray and 1 mentions for Daxor. Daxor's average media sentiment score of 1.87 beat Accuray's score of 0.37 indicating that Daxor is being referred to more favorably in the news media. Company Overall Sentiment Accuray Neutral Daxor Very Positive SummaryAccuray beats Daxor on 7 of the 13 factors compared between the two stocks. Ad WealthPressThe Tesla Trade Is Back In BusinessIf you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get Daxor News Delivered to You Automatically Sign up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DXR vs. The Competition Export to ExcelMetricDaxorSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.58M$4.42B$5.16B$8.74BDividend YieldN/A41.17%5.18%4.08%P/E RatioN/A13.6169.0913.90Price / SalesN/A46.871,271.8686.96Price / CashN/A51.8939.7135.24Price / BookN/A5.516.485.93Net IncomeN/A$13.76M$119.82M$225.73M7 Day Performance-4.86%-6.52%-5.13%-1.34%1 Month Performance-1.31%2.19%-2.71%1.15%1 Year Performance19.65%50.62%31.10%24.02% Daxor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DXRDaxor4.0791 of 5 stars$9.01+2.2%$24.75+174.7%+15.7%$43.58MN/A0.00N/APositive NewsARAYAccuray4.659 of 5 stars$1.70-2.3%N/A-32.5%$170.97M$446.55M-10.00987Analyst DowngradeNVRONevro2.7472 of 5 stars$4.52+11.1%N/A-73.3%$169.36M$425.17M-2.391,215Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeDRTSAlpha Tau Medical2.2736 of 5 stars$2.23+1.4%N/A-27.1%$155.37MN/A-5.5880Upcoming EarningsShort Interest ↑News CoverageBWAYBrainsWay4.3067 of 5 stars$9.12-4.3%N/A+95.3%$152.12M$31.78M91.21120Earnings ReportShort Interest ↓Analyst RevisionNews CoverageGap DownPDEXPro-Dex3.2853 of 5 stars$46.11-3.6%N/A+166.8%$150.32M$53.84M29.94140Positive NewsKRMDKORU Medical Systems3.0134 of 5 stars$3.17+2.9%N/A+44.1%$145.34M$28.52M-12.6880Analyst ForecastNews CoverageSRTSSensus Healthcare4.1171 of 5 stars$7.64+4.8%N/A+263.8%$125.22M$24.41M18.6340Analyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeTLSITriSalus Life Sciences4.3396 of 5 stars$3.93-2.0%N/A-0.5%$119.83M$24.74M-1.57106Analyst ForecastAnalyst RevisionNews CoverageINOInovio Pharmaceuticals3.6666 of 5 stars$4.27-10.5%N/A-92.8%$110.72M$830,000.000.00127Analyst ForecastNews CoverageGap UpQIPTQuipt Home Medical3.2847 of 5 stars$2.56-6.9%N/A-48.3%$110.31M$255.81M-23.271,200News Coverage Related Companies and Tools Related Companies Accuray Alternatives Nevro Alternatives Alpha Tau Medical Alternatives BrainsWay Alternatives Pro-Dex Alternatives KORU Medical Systems Alternatives Sensus Healthcare Alternatives TriSalus Life Sciences Alternatives Inovio Pharmaceuticals Alternatives Quipt Home Medical Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DXR) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Daxor Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Daxor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
